Pfizer Inc. has presented compounds targeting GTPase KRAS and its mutant forms reported to be useful for the treatment of cancer.

Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment of cancer.

Voronoi Inc. has discovered EGFR (Leu858Arg/Thr790Met/Cys797Ser triple mutant) and EGFR (del19/Thr790Met/Cys797Ser triple mutant) inhibitors.

Oregon Health and Science University (OHSU) and the Southern Research Institute have patented compounds reported to be useful for the treatment of alphaviral infections.

Nanjing Zaiming Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTACs) compounds comprising of E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker reported to be useful for the treatment of cancer.

Shanghai Yidi Biotechnology Co. Ltd. has patented dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or PDE4D2 inhibitors reported to be useful for the treatment of autoimmune, metabolic diseases, neurological and inflammatory disorders.

Gilead Sciences Inc. has discovered GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.

Cogent Biosciences Inc. has identified compounds acting as HER2 (erbB2) (L755S mutant) inhibitors reported to be useful for the treatment of cancer.

The University of Kentucky has prepared and tested mithramycin oxime derivatives reported to be useful for the treatment of cancer and neurological disorders.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented tricyclic compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors and thus reported to be useful for the treatment of gram-negative bacterial infections.